Remus Pharmaceuticals Limited has appointed Sharp & Tannan Associates as its Internal Auditor for the financial year 2026-27. The decision was taken by the Board of Directors during a meeting held on May 20, 2026, following the recommendation of the company's Audit Committee. The appointment is made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Appointment Details

The appointed firm, Sharp & Tannan Associates, is a Chartered Accountancy firm with Firm Registration No. 109983W. The appointment is effective from May 20, 2026, and covers the internal audit requirements for the company for FY 2026-27. The company has disclosed that there are no specific relationships between the directors of the company and the appointed auditor that require disclosure.

About the Auditor

Sharp & Tannan Associates was established in 1934 and operates with its head office in Mumbai, along with branches across India, including Ahmedabad and Baroda in Gujarat. The firm currently has nine partners with over six decades of combined experience in internal audit, assurance, and consulting. The firm focuses on risk-based auditing and employs the COSO 1992 framework for its audit processes.

Remus Pharmaceuticals , a prominent player in the Indian pharmaceutical sector, has reported a strong financial performance for the first half of the fiscal year. The company's consolidated results show significant growth in both revenue and profitability, despite a slight decline in margins.

Financial Highlights

Revenue and Profitability

Remus Pharmaceuticals has demonstrated robust growth in its top-line performance. The company's revenue surged to ₹4,000.00 crore in the first half of the current fiscal year, marking a substantial 47% increase from ₹2,720.00 crore reported in the same period last year. This significant revenue growth indicates strong market demand for the company's pharmaceutical products and potentially expanded market reach.

The company's bottom line also showed impressive improvement. Consolidated net profit for the first half rose to ₹175.00 crore, up 34% from ₹131.00 crore in the corresponding period of the previous year. This growth in net profit, while substantial, was not proportional to the revenue increase, suggesting some pressure on profit margins.

Operational Performance

The company's operational performance, as measured by EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization), showed positive growth. EBITDA increased to ₹269.00 crore from ₹211.00 crore year-over-year, representing a 27% rise. However, it's worth noting that the EBITDA margin contracted to 6.70% from 7.80% in the previous year, a decline of 110 basis points.

The reduction in EBITDA margin could be attributed to various factors such as increased raw material costs, higher operating expenses, or pricing pressures in the pharmaceutical market. Despite this margin contraction, the absolute growth in EBITDA indicates that Remus Pharmaceuticals has managed to scale its operations effectively.

Conclusion

Remus Pharmaceuticals' financial results for the first half of the fiscal year paint a picture of a company experiencing strong growth. The substantial increases in revenue and net profit are positive indicators of the company's market position and operational efficiency. However, the slight decline in EBITDA margin suggests that the company may be facing some challenges in maintaining profitability levels amidst rapid expansion.

Investors and market watchers will likely keep a close eye on how Remus Pharmaceuticals manages its growth trajectory while addressing margin pressures in the coming quarters. The pharmaceutical sector continues to be a critical industry, and companies that can balance growth with operational efficiency are likely to stand out in this competitive landscape.